Transcell Oncologics, a leading biotech startup company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad, today announced a breakthrough human Umbilical cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs) based therapy to Covid patients. Transcell Oncologics developed proprietary cell based platform technology HEMATO UC-MSCs with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities.
The research recommends HEMATO UC-MSCs to be administered as “Two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the Covid Patients.” The treatment was associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 “cytokine storm”; with significantly improved patient survival and time to recovery.
Dr. Subhadra Dravida, Founder CEO, Transcell states that: “MSCs have the proven ability to reduce ventilator induced lung damage, reduce cytokine storm, regenerate damaged tissue encouraging practitioners to use them for pre-treating the Covid patient in the hospital. HEMATO UC-MSCs fall in that category that per se do not cause any adverse effects, easy to administer, proven to be safe for human application, with added benefits like no damage caused to any organ. It gives an alternate opportunity to the practitioners in India to treat the increasing Covid-19 cases in the country. The advantage of the therapy is this new way of curing covid patients in real time to SAVE them and NOT to treat the symptoms alone. Also, if HEMATO UC-MSCs are administered as the first line of treatment followed by concomitant steps to alleviate the associated symptoms in a traditional way, Covid deaths can be dodged”.
The effectiveness of this MSC based technology has been confimed by Cell Transplant Centre, Miami Miller School of Medicine, Jackson Health System, Department of Public Health Sciences, USA on COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS). It has released a detailed Research paper on a randomized Controlled Trial (double blind pase 1/2a) and confirmed the laboratory findings from Transcell Oncologics. HEMATO UC-MSCs are already being used by multiple hospitals in Hyderabad and rest of Telangana to save Covid Patients. Hospitals in other cities are also in the process of starting the treatements.
HEMATO UC-MSCs can be delivered pan India within 48 hours and have been specially treated for storage under 2-8 deg C refrigerated conditions for ease of use by the practitioners within 72 hours.
Prof. Appa Rao Podile, Vice Chancellor University of Hyderabad expressed his happiness about the availability of an alternate treatment for the Covid-19 developed by UoH Startup Transcell Oncologics.
Contact details for HEMATO UC-MSCs: Whatsapp or Regular phone: 91-8297256755 or 91-8886666615 or email@example.com
Transcell Oncologics is into drug discovery, enabling cancer medicine and the related invitro testing applications as alternative models to animals in validating pharma, vaccine and cosmetics intended for human consumption. HEMATO Global, product brand from Transcell Oncologics, has over 20 distinct products based on clinically processed stem cells in and as therapeutic tools for imparting transplantations and crystorage services for cancer treatments.